Stanford Brain Tumor Center

Research and Clinical Trials

New types of treatments are always being developed and tested in clinical trials at Stanford. Clinical trials are part of the cancer research process can help determine whether new cancer treatments are better than the standard treatment. Many of today's standard treatments for cancer are based on earlier clinical trials.

For some patients, taking part in a clinical trial may be the best treatment choice. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment. Depending on the research, patients can enter clinical trials before, during, or after starting their cancer treatment.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or to reduce the side effects of cancer treatment. Your oncologist at Stanford will work closely with you to identify appropriate clinical trial(s).

Featured Trials



Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer

Griff Harsh, MD

Phase I/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Scott Soltys, MD

Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

Scott Soltys, MD

Phase II Verubulin (MPC-6827) w/ Radiation Therapy and Temozolomide in Glioblastoma Multiforme

Lawrence Recht, MD

Phase II Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Lawrence Recht, MD

CyberKnife Radiosurgery and Quality of Life

Steven Chang, MD

Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Quynh-Thu Le, MD Iris Gibbs, MD

Featured Research

Stanford researcher Albert J. Wong, MD has discovered a variant of a normal receptor called EGFRvIII expressed only on tumors and not normal brain and created a vaccine targeting this abnormal receptor. This vaccine has moved through phase 2 clinical trials and a multicenter phase 3 clinical trial testing this vaccine is being planned.

Stanford Medicine Resources:

Footer Links: